$17.60 0.54 (+3.17%)
11/6/2009 4:00 PM

Cubist Pharmaceuticals, Inc. (CBST)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

Current Price $17.60 Mkt Cap $1.02B
Open $16.96 P/E Ratio 5.02
Prev. Close $17.06 Div. (Yield) N/A (N/A)
Daily Range $16.96 - $17.60 Volume 876,583
52-Wk Range $13.81 - $28.74 Avg. Daily Vol. 1,024,000

CBST News and Commentary

Caps

How do you think CBST will perform vs the S&P 500?

Add Stock to Watchlist

All Members

238 Outperform
16 Underperform
 

All-Star Members

66 Outperform
6 Underperform
 

Wall Street

10 Outperform
3 Underperform
 

Top CBST Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mrindependent (98.79)
Submitted October 28, 2009

The downside to Cubist Pharmaceuticals is the fact that the company is currently a one trick pony. Substantially all of its revenues and profits come from one drug - Cubicin. On the other hand, the company does have a number of promising trials in… More

0 Comments | Reply | Report this Post

narlinbeaty (56.53)
Submitted May 17, 2008

This company make a drung called Daptomyocin. The drug is affective against MRSA and is used internationally for skin infections and bactermia. In many ways ths drug is a heavy hitting antiboitic used has last line of defense in the hospital setting.… More

1 Comment | Reply | Report this Post
CBST VS S&P 500 (SPY)

Fools bullish on CBST are also bullish on:

Fools bearish on CBST are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about CBST.

Recs

0
Member Avatar toolboy2 (98.13) Submitted: 11/4/2009 9:10:26 PM : Outperform Start Price: $16.93 CBST Score: +2.70

Initiated coverage on these guys last month. They develop drugs in the acute care environment, such as skin and blood infections. Excellent fundamentals: low P/E and PEG ratios, very healthy profit margins and ROE north of 60%. Only drawback for me is their debt load (D/E=0.55), but that's to be expected in the biopharmaceutical industry. With nearly $500 million cash, their balance sheet is in overall good shape.

wallstreetbean.com

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar smith972 (90.02) Submitted: 11/4/2009 6:19:39 PM : Outperform Start Price: $16.75 CBST Score: +3.68

Cubist maybe a takeover target.

Report this Post 0 Comments | Reply | Permalink

Recs

1
Member Avatar mrindependent (98.79) Submitted: 10/28/2009 2:07:11 PM : Outperform Start Price: $16.95 CBST Score: +1.98

The downside to Cubist Pharmaceuticals is the fact that the company is currently a one trick pony. Substantially all of its revenues and profits come from one drug - Cubicin. On the other hand, the company does have a number of promising trials in the works that could result in a significant product line expansion. Return on equity is excellent . The balance sheet is sound with $4.50 per share in net cash and the price seems right at 2.2 times book value. After subtracting $4.50 from the share price to reflect the benefit from the company's net cash on hand, I get an adjusted share price of $12.50, which is approximatley 8 times the 2010 estimated earnings per share. This company could be an attractive acquisition target.

Report this Post 0 Comments | Reply | Permalink
View All 35 Pitches »

Leaderboard

Find the members with the highest scoring picks in CBST.

Score Leader

GrandmasterC00

GrandmasterC00 (< 20) Score: +65.32

The Score Leader is the member with the highest score across all their picks in CBST.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
hwyman64 96.18 11/12/2008 Underperform 3W $24.25 -27.42% +26.86% +54.28
lwc123 76.41 1/8/2009 Underperform 3Y $24.82 -29.09% +20.92% +50.01
BLOWKE < 20 10/16/2008 Underperform 3W $19.50 -9.73% +22.42% +32.15
riskybus < 20 3/2/2009 Underperform NS $14.11 +24.73% +50.34% +25.61
jeffbenes 23.62 2/1/2008 Outperform NS $17.09 +2.98% -19.06% +22.04
RICKDBELL 76.84 2/1/2008 Outperform 5Y $17.09 +2.98% -19.06% +22.04
VanGundy1 31.72 1/19/2007 Outperform 5Y $17.70 -0.56% -20.42% +19.86 1 Comment
germbuster 33.31 3/24/2008 Outperform NS $17.20 +2.33% -16.66% +18.99
Oneofeach 32.64 6/17/2008 Outperform 3Y $17.68 -0.45% -18.26% +17.80
UtahHick 29.02 2/4/2008 Outperform 1Y $18.04 -2.44% -19.80% +17.36
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackOppenheimer 26.63 8/6/2009 Underperform NS $20.57 -15.80% +4.83% +20.63 10/29/2009 @ $17.32
TrackWedbush < 20 3/20/2009 Outperform NS $15.70 +12.10% +39.62% -27.51
TrackThinkEquity 69.79 2/20/2009 Outperform NS $17.00 +3.53% +42.13% -38.60
TrackLeerinkSwan 84.26 12/8/2008 Underperform NS $25.88 -31.99% +21.58% +53.57
TrackRodmanRen < 20 11/20/2008 Outperform NS $22.19 -20.68% +37.17% -57.85
TrackMerriman < 20 10/30/2008 Outperform NS $22.75 -22.64% +14.41% -37.05
TrackJimCramer < 20 10/29/2008 Outperform 3W $22.35 -21.25% +18.08% -39.33
TrackNeedham < 20 7/1/2008 Outperform NS $18.01 -2.28% -12.69% +10.41
TrackStanfordRes 80.42 1/24/2008 Outperform NS $19.07 -7.71% -16.56% +8.86
TrackRWBaird 85.02 1/15/2008 Outperform NS $21.50 -12.84% -24.78% +11.94 10/7/2009 @ $18.74
TrackStifel 94.70 7/19/2007 Outperform NS $22.85 -22.98% -27.34% +4.36
TrackLazardCapit < 20 4/19/2007 Underperform NS $20.79 +9.91% +6.29% -3.61 7/19/2007 @ $22.85
TrackJMP < 20 1/5/2007 Outperform NS $17.07 +3.10% -19.54% +22.65
TrackJefferies 75.83 10/16/2006 Outperform NS $22.62 -22.19% -16.70% -5.49
TrackMatrix 89.45 8/31/2006 Underperform NS $23.52 -25.17% -12.72% +12.45

Featured Broker Partners